HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Keros Therapeutics (NASDAQ:KROS) and maintained a $100 price target.
June 09, 2023 | 2:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Keros Therapeutics and maintained a $100 price target.
The reiteration of a Buy rating and maintenance of a $100 price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for Keros Therapeutics. This news is likely to have a positive short-term impact on KROS stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100